Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Twist Bioscience Corporation (TWST)

173.45 +13.60 (+8.51%)
At close: October 28 at 4:00:01 PM EDT
169.37 -4.08 (-2.35%)
Pre-Market: 5:43:22 AM EDT
Trade TWST on Coinbase
Chart Range Bar
Loading chart for TWST
  • Previous Close 159.85
  • Open 160.44
  • Bid 127.32 x 200
  • Ask 204.71 x 200
  • Day's Range 159.03 - 178.53
  • 52 Week Range 23.30 - 219.71
  • Volume 3,478,536
  • Avg. Volume 2,284,443
  • Market Cap (intraday) 11.5B
  • Beta (5Y Monthly) 2.19
  • PE Ratio (TTM) --
  • EPS (TTM) -2.23
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 168.25
  • Motley Fool Rating Bullish

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

www.twistbioscience.com

979

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TWST
446.82%
S&P 500 (^GSPC)
13.13%

1-Year Return

TWST
416.68%
S&P 500 (^GSPC)
12.38%

3-Year Return

TWST
1,047.92%
S&P 500 (^GSPC)
88.08%

5-Year Return

TWST
42.57%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 118.38M
Earnings -35.05M
Profit Margin -29.61%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
-38.0%
-36.0%
-34.0%
-32.0%
-30.0%
-28.0%

Analyst Insights

View More

Analyst Price Targets

45.00 Low
168.25 Average
173.45 Current
215.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 115 -> 190

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.66%

  • Return on Assets (ttm)

    -13.09%

  • Return on Equity (ttm)

    -29.59%

  • Revenue (ttm)

    431.8M

  • Net Income Avi to Common (ttm)

    -136.72M

  • Diluted EPS (ttm)

    -2.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    166.84M

  • Total Debt/Equity (mrq)

    24.36%

  • Levered Free Cash Flow (ttm)

    -64.82M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: